Search results: (10000)
News Efficacy and Safety of Etanercept in the Therapy of Arthritis
A review by experts from Genoa, Italy, focused on the available knowledge regarding the efficacy and safety of etanercept in the treatment of inflammatory rheumatic diseases.
News Familial Hypercholesterolemia and COVID-19: Connections and Risks
Patients with familial hypercholesterolemia (FH) likely have a higher risk of COVID-19 complications both in the acute phase of the infection and for a relatively long period after its occurrence.
News Thinking About Idiopathic Pulmonary Fibrosis?
Idiopathic pulmonary fibrosis (IPF) is one of the most prognostically severe and difficult-to-treat lung diseases. It affects about 5 million people worldwide, with an estimated incidence in the Czech Republic of 1/100,000 inhabitants. Although it is a relatively rare disease, due to its high mortality rate (the median survival of untreated patients is 2−3 years), it is essential to have a basic awareness of the possible symptoms of IPF. Expert sources even state that, according to statistics, only pancreatic cancer leads to a faster death compared to untreated pulmonary fibrosis.
News IPFchecker Project Helps Detect Patients with Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis is a serious progressive disease of the lung tissue of unclear etiology. Highly effective antifibrotic therapy is used in treatment, which can significantly prolong the lives of patients. However, timely detection of the disease is necessary for treatment success. For this purpose, the IPFchecker web application has been created, which helps radiologists and pulmonologists with more accurate diagnosis and timely detection of the disease.
News Idiopathic Pulmonary Fibrosis: Can This Disease Be Named More Precisely?
Much about idiopathic pulmonary fibrosis (IPF) is still unknown. Some experts would like to reclassify this disease. What classification options are available? What would a focus on the "progressive fibrotic phenotype" in research mean? And what would a change in classification mean for patients?
News Patient with a History of DOAC Usage in Neurological ICU with Stroke – Case Study
How should we approach patients with a stroke who are taking direct oral anticoagulants (DOACs) and correctly assess the situation? When should we administer the available antidote according to guidelines? The following case study from the Regional Hospital Liberec illustrates this increasingly common situation.
News Increase in Thyroid Cancer Incidence Due to the Coronavirus Pandemic?
According to available data, COVID-19 disease does not worsen the course of thyroid cancer. However, the restriction of medical care during the pandemic is associated with concern about an increase in the incidence of this malignant disease and the associated morbidity and mortality.
News Reasons for Nonadherence to Statin Therapy - Survey Results Among Patients
Adherence to statin therapy remains suboptimal despite its proven benefits in reducing cardiovascular risk in individuals with dyslipidemia. Recently published survey results conducted among patients prescribed statins have identified barriers preventing proper adherence to this treatment.
News Hodgkin Lymphoma in a Summary of News from Post-ASH 2021
Dr. Anna Suredová from the Clinical Hematology Department of the Catalonian Oncology Institute in Barcelona, newly elected president of the European Society for Bone Marrow Transplantation (EBMT), also remotely participated in this year's Prague Hematology Days (PHD 2022). In her lecture, she presented an overview of highlights from 4 clinical studies regarding Hodgkin lymphoma (HL) presented during the Post-ASH 2021 meeting.
News Frequent Nausea During Chemotherapy Despite Antiemetic Prophylaxis
Current clinical research has focused on vomiting as a primary issue in the occurrence of CINV (chemotherapy-induced nausea and vomiting) and, using recommended antiemetic prophylaxis, this problem has been relatively well managed. However, the incidence and impact of nausea are underreported. We present the results of an observational study that evaluated the incidence of nausea in patients undergoing chemotherapy.
News Position of Parenteral Therapy in Patients with Severe COVID-19 Disease
Patients with severe COVID-19 disease are at risk of developing acute respiratory insufficiency requiring non-invasive or invasive pulmonary ventilation. Intensive care therapy is associated with a high risk of severe malnutrition. According to current recommendations by the European Society for Clinical Nutrition and Metabolism, parenteral therapy plays an important role in the nutrition of patients.
News Diagnosis, Treatment, and Outcomes Achieved in Patients with Non-Small-Cell Lung Cancer in Central Europe
In June 2020, the journal Radiology and Oncology published the results of an analysis of data from patients with stage III non-small-cell lung cancer (NSCLC) from a Central European registry. A large team led by Czech experts focused on the diagnostic and therapeutic procedures used and the treatment results achieved in real-world practice.
News Options for Reducing or Discontinuing TPO-RA Therapy in ITP Patients − Expert Consensus
There are currently no clear recommendations regarding dose reduction or discontinuation of thrombopoietin receptor agonists (TPO-RA) in patients with immune thrombocytopenia (ITP). A consensus by British authors offers insights into current clinical practice and the related issues.
News New ESMO Recommendations for Investigating Circulating Tumor DNA
Liquid biopsy has been discussed in oncology for several decades. As we move from conference abstracts to its real-world application in clinical practice, the new recommendations of the European Society for Medical Oncology (ESMO) describe the examination of circulating tumor DNA from peripheral blood.
News Finding Balance Between Intracranial Efficacy and Adverse Effects of ALK Kinase Inhibition
More than 7 years – that is the current median survival of patients with non-small cell lung cancer (NSCLC) with a mutation in the anaplastic lymphoma kinase (ALK) gene who are receiving targeted therapy. Therefore, the quality of life of patients on treatment and the search for a balance between its antitumor efficacy and adverse effects (AEs) is becoming the focus of clinical research. Recently, lorlatinib has been discussed in this context.
News Lorlatinib as an Alternative to CNS Radiotherapy in Patients with NSCLC − Case Studies
Two remarkable case studies from authors at the Netherlands Cancer Institute Antoni van Leeuwenhoek in Amsterdam present patients with advanced NSCLC with metastatic CNS involvement. Treatment with crizotinib led to good control of pulmonary involvement but did not affect metastatic CNS involvement. The introduction of lorlatinib subsequently led to rapid improvement in neurological symptoms, which was also confirmed by CNS imaging.
News Efficacy of Lorlatinib in Patients with ROS1-Positive NSCLC in Clinical Practice
Interesting real-world data have been brought by a study on the efficacy of lorlatinib in patients with non-small cell lung cancer (NSCLC) with a mutation in the ROS1 gene.
News COVID Pneumonia: How Can Erdosteine Help and What Did a Clinical Study Suggest?
When patients who have recovered from COVID pneumonia begin home treatment, they are often far from being symptom-free. General practitioners and outpatient pulmonologists often have to address these persistent symptoms. According to a study conducted by Recipharm, erdosteine may be a suitable adjunct treatment for these patients, even when they have negative COVID-19 tests. Why is this the case?
News Cognitive changes in MS – what can teriflunomide do?
In Phase III clinical trials, teriflunomide demonstrated its ability to slow down brain tissue atrophy in patients with relapsing-remitting multiple sclerosis (RRMS). What impact did the treatment have on the cognitive state of these patients?
News Impact of the COVID-19 Pandemic on People with Schizophrenia Spectrum Disorders
The COVID-19 pandemic has a far-reaching impact on the physical and mental health of the global population. The current situation poses an undue burden on patients suffering from schizophrenia as well as other psychiatric disorders. According to recent studies, individuals with schizophrenia spectrum disorders have higher mortality rates and worsening disease progression or overall quality of life.
News From Hell to the Light at the End of the Tunnel – A Task for Eletriptan
In recent months, under the spotlight of new biological treatments, the focus has been predominantly on the prophylactic treatment of migraines. However, we should not forget about acute therapy. In this indication, the pharmacological group of triptans is dominant. So, does eletriptan reliably stop the hell named a migraine attack? And is the response to this drug consistent?
News Spectrum of Mechanisms of Action of Fenfluramine in the Treatment of Rare Epilepsies
Fenfluramine (FFA) is an anticonvulsant used in the treatment of rare epilepsies such as Dravet syndrome and Lennox-Gastaut syndrome. In addition to effectively reducing seizure frequency, it also mitigates non-seizure comorbidities in patients with these conditions. Last year, Belgian authors published a detailed review of all its described mechanisms of action. They also explain how these mechanisms might contribute to the clinical benefits of FFA beyond seizure suppression, such as reducing the risk of sudden unexpected death in epilepsy (SUDEP) or improving executive functions.
News Potential of Aloe to Reduce Severity of Symptoms in Patients with IBS − What Emerged from the Analysis of Fecal Microflora and Metabolite Profiles?
Current treatment options for irritable bowel syndrome (IBS − irritable bowel syndrome) are relatively limited. This increases interest in complementary and alternative therapy options with plant preparations. One modality used to alleviate IBS symptoms is Aloe barbadensis Mill. The aim of a clinical study by Swedish researchers was to assess the effect of aloe on IBS symptoms compared to a control treatment with inulin.